In commercial broiler and layer operations where medication is administered through proximal nipple drinkers and header tanks, Chaige Jieji Powder Veterinary Grade API is processed into water-soluble granules or water-soluble powders rather than direct crude powder due to dust suppression, dose uniformity, and solubility requirements. The manufacturing line for this downstream form is governed by the Chinese Veterinary Pharmacopoeia 2020 monograph for Chai Ge Jie Ji San, China Veterinary Drug GMP as amended through 2020, and, for export into EU territories, Commission Regulation (EU) 2019/6; feed and water medication plants may additionally apply ISO 22000:2018 for cross-contamination control. In the dry-blend step, the API is incorporated at 18–25% w/w of the granule formulation, with 45–55% w/w anhydrous dextrose as a water-solubilising carrier, 8–12% w/w citric acid monohydrate to buffer source water alkalinity, 3–5% w/w povidone K30 as binder, 2–4% w/w sodium starch glycolate as disintegrant, and 0.5–1.0% w/w colloidal silicon dioxide as flow aid. Process equipment on a typical veterinary premix line includes a 500 L stainless steel ribbon blender with edge-sweep clearance ≤5 mm, a high-shear granulator run at impeller 120–180 rpm and chopper 1,000–1,500 rpm for 6–10 min, and a fluidised-bed dryer operated at inlet air 55–65°C until granule moisture is ≤3.5% by loss on drying per CVP 0831. The dried granule is dry-sieved to 20–60 mesh; particles below 60 mesh are recycled by re-wetting, while oversize above 20 mesh is milled through a 0.8 mm screen. Finished water-soluble granules and water-soluble powders are packaged as 100 g, 500 g, and 1 kg foil-laminated sachets or HDPE jars with induction sealing. At the farm, the granules are reconstituted at 0.5–1.5 g/L drinking water, delivering approximately 0.09–0.375 g/L of the API depending on target flock dosage and water intake. A documented operational boundary is that hard water containing bicarbonate above 250 mg/L reduces solution clarity and can precipitate water-insoluble oleanane-type saponin fractions; therefore, pre-dissolution in demineralised water or incorporation of 0.3% w/w sodium hexametaphosphate in the granule matrix is required where source water hardness exceeds this threshold.

Nursery Pig Feed Premix Dilution Geometry and Segregation Control

Medicated feed premix manufacture is selected for nursery pig operations where individual animal dosing is not feasible and a scheduled in-feed therapy is preferred during post-weaning fever events. The addition ratio of Chaige Jieji Powder Veterinary Grade API in the intermediate premix is 4–8% w/w, loaded onto a carrier of ground corncob or defatted rice bran with particle size 300–600 µm and bulk density 0.40–0.55 g/mL, followed by addition of 0.5–1.0% w/w vegetable oil as dust suppressant and 0.2–0.5% w/w fumed silica as flow conditioner. Final feed inclusion rate is usually 0.5–2.0 kg of premix per tonne of complete feed, equivalent to 20–160 g of API per tonne, but the exact level must be fixed by the approved veterinary medicinal product dossier and target species dosage. Production is performed in a twin-ribbon mixer with 1.5–2.0 m³ working volume, mixing time 12–20 min at 20–30 rpm, after pre-blending the API with an equal weight of carrier to avoid high-active pockets; post-mixing coefficient of variation for marker uniformity is specified at ≤5.0% by near-infrared or HPLC. During packaging into 1 kg, 5 kg, and 25 kg foil-lined paper bags, the pack-off hopper is kept at ≤30°C and ≤55% RH because prolonged exposure of the API to moisture above 8.0% accelerates hydrolysis of ester-linked saikosaponins and reduces assay recovery. Compliance standards for this downstream use include China Veterinary Drug GMP for premix plants, the Chinese Veterinary Pharmacopoeia 2020 monograph for the finished premix, and Commission Regulation (EU) 2019/6 for export; if the product is handled in an integrated feed mill, ISO 22000:2018 hazard analysis applies to cross-contamination and mycotoxin controls. The terminal finished product type is a medicated premix for in-feed use in nursery pigs, supplied in multi-wall bags with an inner polyethylene liner and labelled with the approved withdrawal period. A documented incompatibility is the avoidance of simultaneous inclusion with bentonite or other high-cation-exchange clays above 1.0% w/w because such clays bind alkaloid and saponin fractions and reduce intestinal bioavailability of the active markers in batch trials. Published data for this specific premix configuration may be limited in the export dossier, so pilot-scale homogeneity and stability runs are required before commercial batch release.

What Depyrogenation and Sterile Filtration Parameters Define Veterinary Injectable Solutions of Chaige Jieji Powder?

The injectable route for Chaige Jieji Powder Veterinary Grade API is concentrated in swine and large-animal antipyretic therapy where oral administration is impractical during acute fever and inappetence. Sterile manufacturing is governed by China Veterinary Drug GMP sterile annex, Chinese Veterinary Pharmacopoeia 2020 General Chapters 1101 sterility, 1143 bacterial endotoxin, and 0901 clarity of solution, with EU importers requiring compliance with Commission Regulation (EU) 2019/6 and Ph. Eur. 2.6.14 for bacterial endotoxin. The dry powder API is reconstituted in Water for Injections at 50–80 g/L in a jacketed stainless steel dissolution tank maintained at 40–50°C with bottom-sweep agitation 80–120 rpm for 40–60 min. The resulting liquor is adjusted to pH 6.8–7.4 with 0.1 mol/L phosphate buffer or 1% w/v sodium hydroxide solution. Pharmaceutical-grade activated carbon is added at 0.05–0.1% w/v and mixed for 20–30 min at 55–60°C to adsorb endotoxin, proteins, and oxidized polyphenols; subsequent clarification proceeds through a plate-and-frame depth filter with 0.45 µm polyethersulfone or polypropylene media, followed by a 0.22 µm sterilising-grade filter in a single-pass or duplex configuration. Addition ratio of API to final injectable volume is most commonly 5–10% w/v for finished products labelled as 0.5 g/10 mL to 1.0 g/10 mL single-dose or multi-dose presentations, though exact strength is set after assay of saikosaponin and puerarin marker content. Terminal sterilisation at 121°C for 15 min is generally avoided because thermolabile saikosaponin glycosides may degrade above 100°C and the steriliser load may develop gelling of polysaccharide fractions; published stability data for terminal sterilisation of this specific API mixture is limited, and aseptic filtration with aseptic filling is therefore specified unless a batch-specific heat-penetration and marker-degradation study demonstrates retention ≥95%. Aseptic filling is carried out on a linear or rotary vial line under Grade A unidirectional airflow with Grade B background per EU GMP Annex 1, with fill volume control ±1.0%. Finished injectables are 10 mL, 20 mL, and 50 mL Type II glass vials with bromobutyl rubber stoppers and aluminium flip-off seals, stored below 25°C and protected from light. Endotoxin acceptance for intravenous-grade material is <0.5 EU/mL, while intramammary and intramuscular lines typically specify <2.5 EU/mL unless the marketing authorisation sets a stricter limit.

Compressed tablets and hard capsule intermediates for companion animal antipyretic formulations are manufactured from Chaige Jieji Powder Veterinary Grade API by wet granulation rather than direct compression because the raw powder has low bulk density 0.35–0.50 g/mL and poor flow, with Carr index typically above 30 unless granulated. The formulation is designed to meet China Veterinary Drug GMP provisions for oral solid dosage forms, Chinese Veterinary Pharmacopoeia 2020 General Chapter 0921 disintegration, 0923 tablet friability, and 0831 loss on drying; for export to the United States the finished product must comply with FDA 21 CFR 210/211 current good manufacturing practice and, where applicable, VICH GL 1 stability testing for new veterinary medicinal substances. The tablet core composition places the API at 30–45% w/w, with microcrystalline cellulose PH102 at 25–35% w/w, sodium starch glycolate at 10–15% w/w, crospovidone at 3–5% w/w, povidone K30 binder solids at 5–10% w/w, and magnesium stearate at 0.5–1.0% w/w added after drying; capsule fill after the same granulation contains API at 45–65% w/w, lactose monohydrate at 20–35% w/w, sodium starch glycolate at 4–6% w/w, and colloidal silicon dioxide at 0.5–1.0% w/w. Wet granulation is performed in a high-shear mixer at impeller 150–250 rpm and chopper 1,000–2,000 rpm for 5–8 min, followed by fluidised-bed drying at inlet air 50–60°C until granule moisture reaches 2.0–3.0% w/w. The dry granules are milled through a 1.0 mm screen and compressed on a rotary tablet press with precompression force 3–5 kN and main compression force 12–20 kN, yielding tablets with hardness 50–80 N, friability <1.0%, and disintegration ≤15 min in 900 mL purified water at 37°C per CVP 0921; encapsulation is performed on a dosing-disc or tamping-pin machine into size 3 or 4 hard gelatin capsules. Terminal finished product forms are 50 mg, 100 mg, and 250 mg film-coated tablets and 125 mg, 250 mg hard gelatin capsules for cats and dogs, packed in 10×10 blister strips or 60 cc HDPE bottles with desiccant. A process limitation is that hygroscopic polysaccharide fractions in the API may cause sticking at relative humidity above 60%; tablet and encapsulation rooms are therefore kept at 40–50% RH, and direct compression is not recommended unless the API is spray-dried onto a silica or starch carrier.

When Effervescent Boluses Are Compressed for Ruminant Oral Administration in High-Humidity Feedlots

In calf and lamb receiving yards where water lines are shared and feed intake is erratic, effervescent boluses containing Chaige Jieji Powder Veterinary Grade API are produced by direct compression in climate-controlled suites to provide a single-animal oral dosage form that disperses in 3–5 min in room-temperature water or saliva. The bolus formula uses the API at 20–30% w/w, an effervescent couple of sodium bicarbonate at 25–35% w/w and anhydrous citric acid at 20–30% w/w, sorbitol at 10–15% w/w as sweetening filler, polyethylene glycol 6000 at 3–5% w/w as binder, and sodium stearyl fumarate at 0.5–1.0% w/w as lubricant. Direct compression is conducted on a rotary tablet press in a dehumidified suite at 20–25°C and 25–35% RH; compression force is 15–25 kN to produce a 5 g or 10 g bolus with hardness 70–100 N, friability <0.8%, and compressive strength sufficient for push-through blister packaging. Because the API contains hygroscopic oligosaccharides, premature effervescence occurs if granulation moisture exceeds 1.5% w/w; the dry mix is therefore screened through a 0.6 mm sieve and the press is fitted with a dry-air purge at ≤10% RH. Compliance is established through the Chinese Veterinary Pharmacopoeia 2020 General Chapter 0921 disintegration time for effervescent tablets, China Veterinary Drug GMP for solid oral dosage lines, and Commission Regulation (EU) 2019/6 for third-country marketing authorisation; if organic certification is requested for the finished product, the manufacturing site may also need to demonstrate compliance with the applicable organic livestock input standard in the destination market. The terminal finished product type is an effervescent bolus, typically 5 g for lambs and 10 g for calves, packed in 4×5 aluminium-aluminium blister strips or 10-count polypropylene tubes with desiccant caps. A key stability constraint is that storage above 30°C or 60% RH causes bicarbonate-citric acid reaction under pressure, leading to blister dome deformation; stability protocols per VICH GL 1 therefore include a 40°C/75% RH stress cycle and a 25°C/60% RH long-term condition with visual inspection at 0, 1, 3, 6, 12, 24 months.

Oral Drench Solutions for Feedlot Cattle Demand Sequential pH Adjustment and Filtration

Feedlot cattle and sheep drench manufacturing uses a liquid oral route when animals refuse medicated water and require individual administration via balling gun or drenching nozzle. The manufacturing process starts with Chaige Jieji Powder Veterinary Grade API addition to purified water at 40–55°C in a 300–500 L jacketed tank with propeller mixer at 60–100 rpm, achieving a working concentration of 8–12% w/v dry powder equivalent in the final drench. The pH is adjusted in sequence: first, a 0.1 mol/L citric acid solution is added to pH 5.0–5.5 to hydrolyse insoluble calcium salts and improve extraction of basic alkaloid fractions; after 30 min, the pH is raised to 6.5–7.0 with 0.1 mol/L sodium hydroxide to stabilise saponin glycosides. The drench is then clarified through 0.45 µm polypropylene depth media and, where long-distance shipping is expected, preserved with sodium benzoate at 0.1–0.2% w/w and potassium sorbate at 0.05–0.1% w/w. Filling is performed on a peristaltic pump line with fill volume accuracy ±1.5% into 100 mL, 250 mL, and 1 L high-density polyethylene bottles with tamper-evident caps. Compliance standards include the Chinese Veterinary Pharmacopoeia 2020 oral liquid monograph, China Veterinary Drug GMP, and Commission Regulation (EU) 2019/6 for imported oral solutions; microbial limits per CVP 1105 for total aerobic count and CVP 1106 for specified pathogens are applied to non-sterile oral liquids. Terminal finished product type is an oral drench solution for cattle, sheep, and goats packaged in HDPE bottles with dose-marked dispensing cups or graduated adaptors. A documented limit is that separation of pectin-like polysaccharides occurs at ethanol concentrations above 10% v/v or when the solution is stored below 4°C; such solutions must not be frozen, and cold-chain distribution is not recommended because thawed pectin gels block drench nozzles with inner diameters below 4 mm.